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Modified nucleosides, regarded as indicators for the whole-body turnover of RNAs, are excreted in abnormal amounts in the urine of
patients with malignancies. To test their usefulness as tumour markers and to compare them with the conventional tumour markers,
fractionated urine samples were analysed using chromatography. The excretion patterns of nucleosides of 68 cancer patients with
malignant and benign tumours and 41 healthy controls have been studied. Significant elevations in the total sum and the
concentrations of at least three (or four) of indicator nucleosides cytidine, pseudouridine, 2-pyridone-5-carboxamide-N1-
ribofuranoside, N2,N2-dimethylguanine, 1-methylguanosine, 2-methylguanosine and 1-methyladenosine indicate a tumour with a
sensitivity of 54% (77%) and a specificity of 86% (98%). Using an artificial neural network analysis, a sensitivity of 97% and a specificity
of 85% were achieved in differentiating between tumour and control volunteers. The comparison with carcinoembryonic antigen,
cancer antigen 15-3 und tissue polypeptide antigen indicates that urinary nucleosides may be useful tumour markers. This study
suggests that the simultaneous determination of modified nucleosides and creatinine in urine samples of patients with cancer leads to
an advantage to current methods and is a useful method to detect cancer early and to control the success of therapy.
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Urinary excretion of modified nucleosides by healthy adults is
relatively low, but is an indication of the whole-body turnover of
ribonucleic acids (RNAs) (Sander et al, 1986; Scho ¨ch et al,
1990a,b; Topp et al, 1993). Urinary excretion of methylated
nucleosides, which results from increased turnover and degrada-
tion of RNA, especially from transfer ribonucleic acid (tRNA), has
been shown to be excreted in increased amounts in the urine of
patients with different types of tumours and AIDS (Nakano et al,
1993; Xu et al, 2000; Yang et al, 2004; Zheng et al, 2005). Elevated
levels of modified nucleosides have been found in urine from
patients with leukaemia and lymphoma (Rasmuson and Bjo ¨rk,
1995), cancer of the lung (McEntire et al, 1989), oesophagus
(Masuda et al, 1993), breast (Rasmuson et al, 1987; Nakano et al,
1993; Sasco et al, 1996; Zheng et al, 2005), renal cell carcinoma
(Koshida et al, 1985), ovarian cancer (Oerlemans and Lange, 1986),
liver cancer (Yang et al, 2004), tumours of the bladder (Kvist et al,
1993), colon cancer (Holstege et al, 1986) and Hodgkin’s disease
(Martinow et al, 1998). One possible cause is the higher turnover
rate of tRNA in tumour tissues than that in normal counterparts as
demonstrated by Borek et al (1977).
For the quantification and identification of these nucleosides,
immunoassays (Masuda et al, 1993; Ishiwata et al, 1995; Sasco
et al, 1996), capillary electrophoresis (Yang et al, 2004; Zheng et al,
2005), column-switching or precolumn methodology (Boos et al,
1988) as well as high-performance liquid chromatography/mass
spectrometry (Dudley et al, 2004) have all been applied. However,
when a broad spectrum of modified nucleosides has to be
determined, the preferred method is high-performance liquid
chromatography (HPLC) (Lakings et al, 1977; Koshida et al, 1985;
Oerlemans and Lange, 1986; Sander et al, 1986; Rasmuson et al,
1987; McEntire et al, 1989; Gehrke and Kuo, 1990; Scho ¨ch et al,
1990a,b; Kvist et al, 1993; Nakano et al, 1993; Topp et al, 1993;
Rasmuson and Bjo ¨rk, 1995; Martinow et al, 1998; Xu et al, 2000;
Yang et al, 2004).
Approximately, 20 out of the now-known more than 90 urinary
metabolites have frequently been used as diagnostic markers.
Elevated concentrations of the following parameters have been
suggested as possible markers: pseudouridine (Psi), 1-methylade-
nosine (m1A), 1-methylguanosine (m1G), 2-methylguanosine
(m2G), 1-methylinosine (m1I), 2-pyridone-5-carboxamide-N1-
ribofuranoside (PCNR) (1–24). The studies have shown that
modified RNA molecules are metabolised, but not reincorporated
into tRNA and excreted in the urine. Modified purines and
pyrimidines, for example, pseudouridine, 5,6-dihydrouridine,
N2,N2-dimethylguanosine and N6-threoninocarbonyladenosine,
which are found only in tRNA, are quantitatively excreted in
human urine (Borek et al, 1977; Sander et al, 1986; Scho ¨ch et al,
1990a; Topp et al, 1993). Consequently, all urine contains some
modified nucleosides and the levels of modified nucleosides in
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surine reflect RNA degradation in the organism. However, all RNAs,
especially tRNA, from neoplastic tissue have a much more rapid
turnover rate than that of the corresponding healthy tissue (Borek
et al, 1977). In addition, every tumour examined contains
hyperactive tRNA methyltransferases (Lakings et al, 1977). There
is strong evidence for the participation of other body cells in the
release of modified nucleosides possibly due to tumour–host
metabolic interactions (Borek et al, 1977). The concentrations of
modified nucleosides in urine, primarily degradation products of
tRNA, have been regarded as potential indicators for the whole-
body turnover of RNAs, suggesting them as possible markers for
malignant diseases (Sander et al, 1986; Scho ¨ch et al, 1990a,b;
Nakano et al, 1993; Topp et al, 1993). Sasco et al (1996) evaluated
the prognostic significance of six urinary modified nucleosides
in 68 breast cancer patients and found that excretion of 1-
methylinosine and 1-methyladenosine was even further increased
in patients with more advanced disease.
Nucleosides are an important class of metabolites and have the
potential roles of serving as tumour markers. To further explore
the usefulness of urinary nucleosides as tumour markers, we
optimised the fractionation method and multivariable data
analysis technique.
Developing a new method for fractionating of the nucleoside
fraction using the Baker solid-phase extraction (SPE) system
(Baker, 1997) with 3ml columns with octadecylsilane, we studied
the urinary profiles of nucleosides in patients with malignant
diseases and control subjects. Determining normal nucleoside
levels from ‘normal’ turnover and catabolism of RNA in the urine
of healthy control subjects is necessary to compare the levels in
patients with malignant diseases. A data set of urinary nucleosides
containing all the patients and healthy volunteers was obtained for
the neural network analysis.
MATERIALS AND METHODS
Reagents
The following nucleoside standards were obtained from Sigma
(St Louis, MO, USA): pseudouridine, uridine, cytidine, 1-
methyladenosine, 5-methylcytidine, 7-methylguanosine, inosine,
1-methylinosine, 5-methyluridine, guanosine, xanthosine, 1,7-
dimethylguanosine, 1-methylguanosine, 2-methylguanosine, N2,N2-
dimethylguanine, adenosine, N6-methyladenosine and 3-methylur-
idine. Modified nucleosides were all of HPLC purity grade.
Ammonium dihydrogen phosphate, methanol and acetonitrile
were Baker-analysed HPLC-grade from Baker (Phillipsburgh, NJ,
USA). Distilled, deionised water was obtained from a Milli Q plus
purification system (Millipore, Bedford, MA, USA).
Collection of urine samples and extraction of nucleosides
Patients were completely recruited in the Department of Surgery II
of the Medical Faculty of the University of Leipzig. The
experimental groups consisted of 55 patients (age from 17 to 85
years; mean age 56.9 years) with histologically diagnosed
malignant tumours (group I: 26 breast, eight colon, three
thyroidea, seven sarcomas, two melanomas, two bronchial
carcinomas, three granulomas, two gynaecological, two others,
and group II: 13 patients with benign growths - nine adenomas of
thyroidea, two chondromas, one lipoma, one adenoma of
parathyroidea). Diagnoses of cancer and benign tumours were
made on the basis of usual clinical, laboratory and radiologic
findings and were confirmed by histopathology. In the Department
of Surgery II, the method of staging was used according to the
tumour node metastasis system (Spiessl, 1993). Data on serum
carcinoembryonic antigen (CEA), cancer antigen (CA) 15–3 and
tissue polypeptide antigen (TPA) were provided by the same
hospital. Table 1 shows the clinical characteristics of 55 cancer
patients. The control group was selected from healthy volunteers
(31 students and 10 blood donors) with no manifestation of
disease. Their age ranged from 25 to 70 years (mean age 38.4
years). At the time of the study, all were in good health with none
taking any medications.
The urine samples, from both healthy and tumour patients,
collected were mainly, but not exclusively, of the first thing in the
morning. They were all filtered immediately using a 0.2-mm
membrane cellulose acetate (Sartorius). The filtered urine samples
were stored at  201C until processed. Modified nucleosides keep
stable for at least 2 months when stored at  201C. Urine is
generally filtered sterile, and thus the concentration of nucleosides
are not altered biologically.
The urinary modified nucleosides were extracted on octadecyl-
silane (C18) columns (Baker) possessing a specific affinity for cis-
hydroxyl groups. The columns were preconditioned with 1.0ml
acetonitrile, followed by 5.0ml methanol and 3.0ml aqua dest. The
recovery of nucleosides was estimated from a 0.5ml stock solution
passed through the columns. All analyses of the urine are based on
a 0.5ml volume. The columns were eluted with 2.0ml methanol
and 1.0ml acetonitrile. The samples were then evaporated to
dryness at 501C and dissolved in 0.5ml distilled water. A 20ml
sample volume was injected into a reversed phase (RP) HPLC and
analysed.
Nucleoside and creatinine determinations
The chromatographic method used for the RP liquid chromato-
graphic separation of nucleosides was based on the one developed
by Gehrke and Kuo (1990). The HPLC apparatus (Gynkotek,
Mu ¨nchen, Germany) consisted of a Gynkotek 480 pump gradient,
heated column compartment (Gynkotek), an injector and a UVD
320 photodiode array ultraviolet (UV) detector. Separation was
achieved using an (250 4.6mm ID) LC-18-S Supelcosil column
with guard cartridges (2.1 4.6mm ID) LC-18-S Supelosil (Sigma-
Aldrich, Bellefonte, PA, USA). For the calibration, four different
volumes of a standard solution of nucleosides or creatinine were
mixed with 0.5ml of the internal standard (3-methyluridine), were
treated separately on the SPE columns like the urine samples and
were determined at 210, 245, 254 and 280nm. Peaks in urine
samples were identified by comparing their chromatographic
retentions and UV spectra with known reference nucleosides,
based on diode-array UV/VIS technology.
The nucleoside-to-creatinine ratio was chosen to compare
patients and control subjects and to consider the circadian
rhythm, because a 24-h urine sample was not available. A
substantial element of the procedure is the determination of
nucleosides and creatinine on a simultaneous way.
To determine simultaneously modified nucleosides and creati-
nine, we introduced an analytical fractionation of the sterile urine
samples before the HPLC was carried out. For separation of the
nucleoside fraction, we developed a method using the Baker SPE
system with 3ml octadecylsilane (C 18) cartridges operating under
reduced pressure. The repeatability and reproducibility of nucleo-
side retention time were evaluated on a ‘run-to-run’ basis. The
relative standard deviation (RSD) of the retention times for each of
18 nucleosides was calculated from 10 runs. The recoveries,
determined earlier using urine spiked with the stock solution, were
from 79 to 102%. The reproducibility of the method including the
extraction has been determined in six repetitive analyses using a
same normal spontaneous urine sample from a healthy volunteer
extracted on SPE columns and analysed with the RP–HPLC.
Statistical analysis
The univariate statistics and the nature of the underlying
distributions were determined for each nucleoside. Separate
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sTable 1 Clinical characteristics of (a) breast cancer patients and (b) different types of cancer
Cancer Patient no. Age Sex Cancer stage Metastasis stage CEA
a (lgl
 1) CA 15-3
b (Ul
 1) TPA
c (Ul
 1)
Number of elevated
nucleosides
(a)
Breast cancer 1113 55 F T4N1Mx Tms2 3.1 92.6 110.0 3
1164 61 F T2N1Mx Tms2 1.4 23.6 33.0 6
1165 57 F T3N1M0 Tms2 o1.0 85.6 222.0 1
1166 53 F TxNxM1 Tms2 o1.0 22.8 38.0 6
1167 55 F T2N1Mx Tms2 1.6 17.1 36.0 2
1169 50 F T2N1M1 Tms2 62.7 83.4 273.0 4
1172 52 F T4N0M0 Tms2 1.3 6.8 44.0 6
1187 54 F T2N1M0 Tms2 o1.0 5.2 8.0 3
1193 41 F T1N0Mx Tms2 2.4 12.2 30.0 3
1199 78 F T4N1M0 Tms1 1.8 20.9 67.0 5
1204 52 F T2N0M0 Tms1 2.6 10.1 15.0 5
1209 59 F T1N1Mx Tms2 o1.0 8.7 21.0 2
1213 69 F T2N1Mx Tms2 1.7 29.4 40.0 4
1214 57 F T4NxMx Tms2 1.5 9.0 915.0 4
1215 75 F T4N1M1 Tms2 1.4 24.6 80.0 6
1219 63 F T2NxM0 Tms2 4
1231 52 F T4N0M0 Tms1 o1.0 o5.0 29.0 6
1240 47 F T4N1M1 Tms2 16.4 137.3 450.0 2
1260 74 F T0NxM1 Tms2 1.2 9.8 66.0 4
1272 71 F TxNxM1 Tms2 30.2 37.2 120.0 3
1295 66 F T1NxMx Tms2 2.6 16.0 51.0 3
1299 85 F T2N0M0 Tms1 3
1303 82 F T1N1M0 Tms2 1.5 14.9 63.0 7
1312 56 F T2N0M0 Tms2 1.9 12.1 17.0 8
1324 74 F T1 N0M0 Tms1 1.3 25.2 72.0 1
1334 37 F T4N1M0 Tms2 o0.1 13.41 106.0 2
(b)
Colon Ca. 1112 62 M T3N2M1 Tms2 48.3 300.0 6
1188 41 F TxN0M0 Tms2 140.0 2
1203 72 F NA Tms2 8.9 8.0 5
1205 65 F T3N0M1 Tms2 3
1275 57 M T3N0M0 Tms1 o1.0 1
1267 41 M T4N2M1 Tms2 5.0 2
1279 50 M T4N0M0 Tms2 5
1296 44 F T4N0M0 Tms1 3
Thyreoidea 1202 61 M T4N1M1 Tms2 7
1250 64 F T2N1M1 Tms2 140.0 7
1302 70 F T0N0M1 Tms2 4
Sarkoma 1184 74 F T2N0M0 Tms2 5
1206 50 M NA 5
1218 83 M T2N0M0 Tms1 2
1263 50 F T4N0M1 Tms2 o0.1 11.2 31.0 0
1278 52 M T2NxMx Tms2 1
1289 49 F T2NxM1 Tms2 o1.0 12.6 3
1298 17 M T Mx Tms1 1
Melanoma 1220 62 M T3N2M1 Tms2 4
1287 85 F NA Tms2 6
Bronchial-Ca 1178 65 M T4N3M1 Tms2 3
1236 83 M T2N1M1 Tms2 6.5 2.4 4
Granuloma 1168 53 M Stad. IV a 0
1180 24 F NA 1
1235 75 M NA 3
Gynaecol. Ca 1297 33 F TxNxM1 Tms2 o1.0 12.1 0
1300 59 F TxNxM1 Tms2 2.2 10.2 73.0 6
Other 1268 71 F T4N0M0 Tms2 2.6 5
1237 37 M 6
Average 58.6 4.33 10.1 77.0 4
s.d. 15.0 1.54 3.4
CA¼cancer antigen; CEA¼carcinoembryonic antigen; F¼female; M¼male; s.d.¼standard deviation; TPA¼tissue polypeptide antigen. Tms1 (tumour stage 1): patients have
primary cancer but no evidence of distant metastasis. Tms2 (tumour stage 2): patients have histological evidence of distant metastasis.
aSerum CEA normal: o6mgl
 1.
bCA 15–3
normal: o25Uml
 1.
cTPA normal: o90Uml
 1.
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sunivariate analysis of the 18 variables by using nonparametric
statistics was carried out using the Kolmogorov–Smirnov test,
given the non-normal distribution of half of the parameters
studied. The Wilcox rank sum (U-test) and the Mann–Whitney
test were applied in the comparison analyses of the median using
the SPSS statistical package (Bu ¨hl and Zo ¨fel, 1997). A mean value
of Po0.05 was accepted as significant. Cutoff level was the average
mean concentrationsþstandard deviations of each modified
nucleoside in the urine of the 41 healthy volunteers. To avoid
misclassifications of false positives and false negatives, a neuronal
network analysis was applied to these data. This analysis is based
on the network model developed by Zhao et al (1998) and is also
applied here. Sensitivity and specificity are calculated with the aid
of Baye’s theorem, according to Wagener (1984).
RESULTS
The calibration curves, with a mean correlation coefficient of 0.99,
were obtained for 18 nucleosides and creatinine at four channels.
Repeated runs demonstrate the accuracy and precision of the
technique used (Table 2). The range of standard deviation (RSD) of
the retention is 0.20–1.69. The precision of the method was
determined by six repetitive analyses of a normal male urine
sample. The results in Table 2 show that the method is quantitative
and reproducible. High RSD values were observed for m6A, which
was caused by the transmethylation of m1A to m6A during sample
preparation.
For example, representative chromatograms used for identifica-
tion and quantification of nucleosides are given in Figures 1A and
B showing the separation and resolution of nucleosides by using
the chromatographic conditions described. Figure 1B is a
chromatogram of urine of a malignant human and is representa-
tive of the HPLC method used in this study.
Urine from a total of 41 volunteers with no evidence of disease
was analysed for 18 nucleosides. No significant difference was
obtained between the levels of urinary nucleosides obtained from
30 men and 11 women (P40.05). The mean age was 38.4 years
(range was 25–70 years). No significant differences were found in
the selected seven mean nucleoside values with respect to the age
groups. Most of the nucleoside levels of this work were higher than
the data given in literature.
In Table 3, the cutoff values of the modified nucleosides in the
healthy group are shown serving as reference for the comparison
with malignant tumour groups. Table 3 clearly shows that
concentrations of cytidine, 1,7-dimethylguanosine, 1-methylade-
nosine, 1-methylguanosine, N2,N2-dimethylguanine, 2-methylgua-
nosine, 5-methyluridine, 6-methyladenosine, PCNR and
pseudouridine in urine of patients with cancer were elevated
significantly.
Our data presented in Figure 2 also revealed that the
concentrations from patients with benign tumours were lower
than those of cancer patients. Most modified nucleosides were
found to be elevated, but the extent of the increase varied with each
nucleoside. Levels of modified nucleosides excreted by patients
with primary (stage 1) and of more advanced cancer (stage 2) are
presented in Figure 3. The mean levels of cytidine, 1-methylade-
nosine, N2,N2-dimethylguanine and PCNR in patients with
malignant cancer was higher than that with primary cancer.
Increased numbers of peaks, which also have UV spectra like the
spectra of nucleoside, were observed in samples of tumour patients
in a more advanced stage. The fate of those missing nucleosides is
yet unknown. It has to be assumed that these peaks are not tailings
but real other nucleoside-like compounds.
The diagnostic value of a tumour marker depends on its
sensitivity and specificity.
Significant elevations in concentrations of at least four of the
following parameters cytidine, pseudouridine, 2-pyridone-5-car-
boxamide-N1-ribofuranoside, N2,N2-dimethylguanine, 1-methyl-
guanosine, 2-methylguanosine, 1-methyladenosine and the total
sum of 18 determined nucleosides indicate a sensitivity of 54% and
a specificity of 98% (Table 4a). Assuming that three of the seven
significant nucleoside parameters (given in Table 4b) should cross
the threshold value, a sensitivity of 79% and a specificity of 85%
could be achieved.
To avoid misclassifications of false positives and false negatives,
a neuronal network analysis was applied to these data. The
neuronal net was able to classify one unknown person as healthy
or tumour patient. The result was then compared with the known
Table 2 Analytical characteristics of RP–HPLC and RSD, in series determined in a normal urine sample
Nucleoside Abbreviation
Retention
time mean s.d.
RSD
a
(%)
Linear range
(mmoll
 1)
Average
(nmollmol
 1
creatinine) s.d. 2.72 RSD
b (%)
Pseudouridine Psi 4.96 0.06 1.21 0.010–0.200 73.36 3.968 5.41
Cytidine C 6.30 0.08 1.27 0.010–0.200 42.41 2.969 7.00
1-methyladenosine m1A 10.81 0.16 1.48 0.020–0.080 8.40 1.203 14.32
2-pyridone-5-
carboxamide- PCNR 14.51 0.11 0.59 0.010–0.080 8.74 0.813 9.09
N-1-ribofuranoside
1-methylguanosine m1G 23.61 0.09 0.38 0.010–0.050 2.47 0.524 21.21
2-methylguanosine m2G 24.43 0.17 0.70 0.010–0.050 4.73 1.048 22.16
N2,N2-dimethylguanosine N2,N2Gua 24.90 0.05 0.20 0.010–0.050 0.755 0.131 17.35
adenosine A 25.37 0.21 0.83 0.010–0.050 4.74 1.396 29.45
1-methylinosine m1I 23.20 0.13 0.56 0.010–0.050 5.80 1.158 19.96
3-methylcytidine m3C 9.42 0.07 0.74 0.010–0.050 3.13 0.211 6.74
5-methylcytidine m5C 12.18 0.19 1.56 0.010–0.050 12.53 1.944 15.51
5-methyluridine m5U 18.50 0.08 0.43 0.010–0.200 15.72 4.924 31.32
1,7-dimethylguanosine m1,7G 22.67 0.17 0.75 0.050–0.500 16.03 1.106 6.9
Inosine I 17.69 0.14 0.79 0.010–0.080 6.42 0.786 12.24
6-methyladenosine m6A 32.62 0.28 0.86 0.010–0.050 1.12 0.353 31.52
7-methylguanosine m7G 16.96 1.00 1.00 0.010–0.050 2.08 0.278 13.36
uridine U 8.85 0.15 1.69 0.010–0.100 6.05 0.200 3.31
Xanthosine X 20.86 0.13 0.62 0.010–0.100 25.08 3.880 15.52
HPLC¼high-performance liquid chromatography; PCNR¼2-pyridone-5-carboxamide-N1-ribofuranoside; Psi¼pseudouridine; RP¼reversed phase; RSD
a,b (%)¼relative
standard deviation; s.d.¼standard deviation.
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shealth status of the person. This procedure was conducted for all of
the 109 volunteers. From 68 tumour patients, 66 were classified
correctly as tumour positive and two as tumour negative (false
negative). From the 41 healthy persons, 35 were identified as
healthy and six as false positive. The sensitivity and specificity
were 97 and 85%, respectively.
The concentrations of CEA, CA 15–3 and TPA of these patients
in serum and numbers of elevated nucleosides are given in Table 1.
To distinguish subjects suffering from breast cancer and healthy
subjects, the Baye’s technique has been used (Wagener, 1984) to
study the modified nucleosides resulting in a sensitivity of 76.9%.
Carcinoembryonic antigen and CA 15–3 are conventionally used
as tumour marker for breast cancer (cutoff level CEA¼6mgl
 1;
CA 15–3¼25Uml
 1). From Table 1, only three CEA levels in 24
breast patients and seven CA 15–3 levels in 24 breast cancer
patients were higher than the cutoff value (sensitivity: CEA – 12.5%
and CA 15–3 – 29.2%). Also, TPA has low diagnostic specificity
(29.2%). In this study on women with breast cancer as well as in
patients with different kinds of cancer, the modified nucleosides
have a higher diagnostic sensitivity than CEA, CA 15–3 and TPA
(Table 5).
DISCUSSION
Modified nucleosides have been found in increased amounts in the
urine of cancer patients (Figure 2). These RNA metabolites are not
reincorporated for de novo nucleotide synthesis and, thus,
quantitatively excreted in urine where they are measurable (Borek
et al, 1977; Sander et al, 1986; Scho ¨ch et al, 1990a; Topp et al,
1993). Before the samples could be analysed by HPLC, a treatment
is necessary to remove the proteins. Other authors reported on
using phenyl boronate affinity column for nucleoside isolations
(Koshida et al, 1985; Holstege et al, 1986; Oerlemans and Lange,
1986; Sander et al, 1986; Rasmuson et al, 1987; McEntire et al,
1989; Gehrke and Kuo, 1990; Scho ¨ch et al, 1990a; Kvist et al, 1993;
Nakano et al, 1993; Topp et al, 1993; Rasmuson and Bjo ¨rk, 1995;
Martinow et al, 1998; Xu et al, 2000; Yang et al, 2004) or using the
Baker SPE system with aromatic sulphonic acid (Scho ¨ch et al,
1990b). These fractionation methods of nucleosides from urine
were found to be too complex and time consuming to allow the
analyses of large numbers of urine samples. We applied a
new method using the Baker SPE system, which allowed the
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Figure 1 (A) Chromatograms of RP–HPLC separation of nucleosides in
urine extract from a healthy person. Column: 250 4.6mm Supelcosil LC-
18S; mobile phase: gradient program; UV detection: 254nm; peak
identifications: Psi¼pseudouridine, C¼cytidine, m1A¼1-methyladeno-
sine, PCNR¼2-pyridone-5-carboxamide-N1-ribofuranoside, M1G¼
1-methylguanosine, m2G¼2-methylguanosine, N2,N2 Gua¼N2,N2-di-
methylguanine. (B) Chromatogram of RP–HPLC separation of nucleosides
in urine extract from a cancer patient. Column: (250 4.6mm) Supelcosil
LC-18-S. All other chromatographic conditions were the same as for
Figure 1A.
Table 3 Nucleoside/creatinine ratios in urine of healthy persons and patients with malignant tumours
Healthy persons (n¼41) Malignant patients (n¼55)
Nucleoside (nmollmol
 1) Median 95% percentile Mean Cutoff level Median 95% percentile Mean Significance
Psi 43.23 114.515 52.203 88.008 66.598 185.384 81.927 o0.0001
C 6.012 136.383 26.118 67.89 128.66 426.782 142.181 o0.0001
m1A 5.121 23.356 7.491 14.622 11.58 52.578 17.2 o0.01
PCNR 5.268 16.966 5.508 9.602 8.31 57.557 14.232 o0.0001
m1G 1.616 4.876 1.808 3.296 1.928 12.072 3.536 o0.05
m2G 1.935 7.339 2.277 4.173 2.205 20.392 4.942 o0.05
N2,N2Gua 0.231 2.312 0.556 1.264 1.925 23.705 4.487 o0.0001
A 3.666 18.54 6.558 14.395 2.991 65.264 12.239 NS
m1I 4.362 12.312 5.223 9.23 4.388 75.247 14.63 NS
m3C 3.56 38.463 9.446 22.083 5.964 277.198 31.815 NS
m5C 20.145 54.394 20.408 37.275 24.123 128.998 32.135 NS
m5U 2.748 19.394 4.729 10.119 3.233 44.816 8.241 0.05
m1,7G 1.566 132.683 16.685 56.019 20.747 207.094 45.575 0.001
I 2.875 23.776 6.834 15.991 3.178 18.492 5.166 NS
m6A 0.445 4.05 0.894 2.57 1.189 6.05 1.892 o0.001
m7G 1.365 6.624 1.943 3.574 2.279 23.62 4.684 NS
U 3.376 55.619 7.216 23.087 2.018 63.453 10.819 NS
X 12.615 207.173 27.376 90.301 5.411 303.906 28.63 NS
NS¼no significance; PCNR¼2-pyridone-5-carboxamide-N1-ribofuranoside; Psi¼pseudouridine.
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sTable 4 Discrimination between ‘healthy subjects’ and ‘tumour patients’ with the parameters (C, m1A, PCNR, m1G, M2G, N2,N2 G and sum of 18
determined nucleosides) as tumour markers. False negative/positive depending on elevated nucleosides
Elevated
Number of elevated markers Number of elevated markers in per cent
Nucleosides Mal. tumours Controls All Elevated nucleosides Mal. tumours Controls All
(a)
0 0 9 9 0 0 0.22 0.09 Specificity ¼98%
1 1 11 12 1 0.02 0.27 0.12
2 4 7 11 2 0.07 0.17 0.11
3 6 8 14 3 0.11 0.20 0.15
4 14 5 19 4 0.25 0.12 0.2
5 20 1 21 5 0.36 0.02 0.22 Sensitivity ¼54%
6 9 0 9 6 0.16 0 0.09
7 1 0 1 7 0.02 0 0.01
Sum 55 41 96 Sum 1 1 1
(b)
0 0 9 9 0 0 0.22 0.09 Specificity ¼86%
1 1 11 12 1 0.02 0.27 0.12
2 4 7 11 2 0.07 0.17 0.11
3 6 8 14 3 0.11 0.20 0.15
4 14 5 19 4 0.25 0.12 0.20 Sensitivity ¼79%
5 20 1 1 5 0.36 0.02 0.22
6 9 0 9 6 0.16 0 0.09
7 1 0 1 7 0.02 0 0.01
Sum 55 41 96 Sum 1 1 1
PCNR¼2-pyridone-5-carboxamide-N1-ribofuranoside.
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Figure 2 Mean excretion of modified nucleosides in urine from healthy volunteers (n¼41) and patients with benign (n¼13) and malignant tumours
(n¼55) (P-value for testing against ‘healthy’).
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Figure 3 Mean excretion of modified nucleosides from healthy volunteers (n¼41) and patients with malignant stages (stage 1¼primary cancer (n¼9);
stage 2¼patients have histological evidence of distant metastasis or recidivism (n¼40)).
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of creatinine and of nucleosides. In recent years, a number of
methods based on HPLC have been reported, but little is known
about simultaneous measurements of modified nucleosides and
creatinine.
Random samples can be used when nucleoside levels are
expressed relative to creatinine.
For the evaluation of the method, it was necessary to establish a
reference range within the control group. Eighteen different
modified nucleosides were measured in the urine of 41 healthy
subjects (Table 3). The cutoff values of modified nucleosides are
based on the values of the healthy group, serving as the reference
for comparison of malignant and benign patient groups (n¼55
and 13, respectively). In this study, the concentrations of 10
modified nucleosides were significantly elevated in patients with
malignant diseases and six nucleosides in patients with benign
tumours. The excretion of 1-methyladenosine, cytidine, N2,N2-
dimethyguanine and PCNR were higher in patients, which have
histological evidence of distant metastasis as compared to those in
patients without metastasis, reflecting more advanced disease
(Figure 3). Several modified nucleosides are always elevated in
malignant diseases with varying levels. The following seven
were the most significant ones: cytidine, N2,N2-dimethylguanine,
PCNR, 2-methylguanosine, 1-methylguanosine, pseudouridine and
1-methyladenosine. These nucleosides have already been reported
as useful biochemical ‘indicators’ in malignant diseases (Lakings
et al, 1977; Koshida et al, 1985; Holstege et al, 1986; Oerlemans and
Lange, 1986; Sander et al, 1986; Rasmuson et al, 1987; Boos et al,
1988; McEntire et al, 1989; Gehrke and Kuo, 1990; Scho ¨ch et al,
1990a,b; Kvist et al, 1993; Nakano et al, 1993; Topp et al, 1993;
Rasmuson and Bjo ¨rk, 1995; Martinow et al, 1998; Xu et al, 2000;
Dudley et al, 2004; Yang et al, 2004; Zheng et al, 2005). Cytidine
and uridine were found to be much more increased than reported
in other publications. From Table 3, it can be observed that
modified nucleosides (Psi, C, U, m1A) were more frequently higher
than in the literature. We assume that these higher levels are due
to the minimal sample manipulation during the new treatment
method using SPE. It was also found that differences of nucleoside
excretion exist among patients even with the same stage of tumour.
This is illustrated in Figures 2 and 3, where m1G and m2G show
different levels. This observation underlies the necessity to
measure more than three or four nucleosides to evaluate the
status of a subject. The sensitivity and specificity of the method
applied here (four parameters elevated) were 54 and 98%,
respectively, and, thus, fulfilled the requirements according to
Fateh-Mogdaham and Stieber (1991). According to this, the
diagnostic efficiency of a tumour test is to be fixed at a specificity
of 95%, which results in a sensitivity of 450%. If the intention
is to identify as many tumour patients as possible, the cutoff
should be set low. Subsequently, an increase in the percentage of
false-positive results has been observed, that is, a reduction in
specificity. Based on the selection of three of the seven parameters
above the threshold, a sensitivity of 79% (40 out of 55 patients are
recognised as malignant) and specificity of 86% (five false
positives) were achieved (Tables 1 and 5).
To analyse misclassifications of false positives and false
negatives, an artificial neural network analysis (a pattern recogni-
tion tool) was applied. Application of this powerful method led to
a reduced misclassification (only two out of 68 cases (97%) with
tumours (malignant and benign)). Among healthy volunteers, five
were misclassified as false positive (five out of 41; 84.5%). All in all,
it can be stated that the artificial neural network technique leads to
better results than principal component analysis (the Baye’s
theorem) for the classification of healthy persons and cancer
patients based on nucleoside data (Zhao et al, 1998; Yang et al,
2002). The difference in misclassification between healthy and
tumour patients cannot be explained at present. However, the
authors assume that the threshold of nucleoside concentrations
in the urine may not be exactly enough, that the number of
nucleosides measured may not be large enough and/or that other
specific combinations of nucleosides should be tested. This will be
investigated further. However, McEntire et al (1989) measured 24
nucleosides in serum by HPLC and used a discriminate regression
analysis (STEPDISC) classifying of lung cancer patients. Their
sensitivity reached 84% with a specificity of 79%, showing that the
misclassification rate did not get much better by increasing the
number of nucleosides.
The concentrations of CEA, CA 15–3 and TPA in serum of the
patients with breast cancer (Table 1a) show that the sensitivity of
urinary nucleosides in breast cancer patients was 76.9% (20 out of
26 patients) by using the Baye’s technique. Serum CEA and CA
15–3 are being used in clinics to diagnose breast cancer (cutoff
level: CEA¼6mgl
 1;C A1 5 – 3 ¼25Ul
 1). Table 1 shows a
sensitivity of CEA and CA 15–3 as 12.5 and 29.2%, so the urinary
nucleosides had higher diagnostic sensitivity than serum CEA and
CA 15–3. In another study on women with breast cancer, the
modified nucleosides had a higher diagnostic sensitivity than CEA
and CA 15–3 (Rasmuson et al, 1987; Xu et al, 2000; Zheng et al,
2005). This is of particular interest, because breast cancer is the
major cancer among women all over the world, and the used
markers have low diagnostic sensitivity. Also, TPA in our study,
which has been used as marker for breast cancer, has low
diagnostic specificity (29.2%).
Further studies will be necessary to evaluate the usefulness of
urinary nucleosides in differentiating cancer from other diseases.
Attention may have to be paid to conditions influencing RNA
catabolism other than those occurring in malignancies, for
example, endocrine abnormalities, alcoholism, infections and
renal dysfunction. This may increase the number of false positives.
In summary, we report on a sensitive HPLC method for the
simultaneous determination of a broad spectrum of modified
nucleosides and creatinine in one urine sample. The SPE
fractionation method proposed here is simple and time sparing.
This new preparation requires no extensive purification of the
urine samples and no extensive preparation of columns, and
requires small sample volume (0.5ml) and an elution time of only
60min. Urinary modified nucleosides cytidine, N2,N2-dimethyl-
guanine, PCNR, 2-methylguanosine, 1-methylguanosine, pseudo-
uridine and 1-methyladenosine were found to be a possible
marker for cancer. In such a multicomponent alteration of the
nucleoside levels, a pattern recognition method could reveal more
information on the distinctions between healthy individuals and
cancer patients than the evaluations of the single components.
Compared with the Baye’s theorem, classification by artificial
neural networks is more satisfactory, and it can hopefully be
used as a powerful tool for decisions in the tumour diagnosis.
Simultaneous determination of modified nucleosides and creati-
nine is particularly advantageous in noninvasive diagnostic
procedures.
Table 5 Diagnostic positive ratio of cancer patients based on traditional
biomarkers and on urinary nucleosides (sensitivity)
Traditional biomarkers
CEA CA 15-3 TPA
Urinary
nucleosides
Breast cancer n/N 3/24 7/24 7/24 20/26
Sensitivity (%) 12.5 29.2 29.2 76.9
All kinds of cancer n/N 8/35 7/31 8/28 40/55
Sensitivity (%) 22.9 22 28.6 72.7
CA¼cancer antigen; CEA¼carcinoembryonic antigen; TPA¼tissue polypeptide
antigen.
Modified nucleosides
A Seidel et al
1732
British Journal of Cancer (2006) 94(11), 1726–1733 & 2006 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
sREFERENCES
Baker JT (1997) Instructions for Use. NJ, USA: Phillipsburg
Boos KS, Wilmers B, Schlimme E, Sauerbrey R (1988) On-line sample
processing and analysis of diol compounds in biological fluids.
J Chromatogr B 456: 93–99
Borek E, Baliga BS, Gehrke CW, Kuo KC, Belman S, Troll W, Wallkes TP
(1977) High turnover rate of transfer RNA in tumor tissue. Cancer Res
37: 3362–3366
Bu ¨hl A, Zo ¨fel P (1997) SPSS fu ¨r Windows Version 6. Addison-Wesley
Publishing Company
Dudley E, Lemiere F, VanDongen WR, Tuytten RS, El-Sharkawi S, Brenton
AG, Esmans L, Newton RP (2004) Analysis of urinary nucleosides. IV.
Identification of urinary purine nucleosides by liquid chromatography/
electrospray mass spectrometry. Rapid Commun Mass Spectrom 18:
2730–2738
Fateh-Mogdaham A, Stieber P (1991) Tumormarker und ihr sinnvoller
Einsatz.,M u ¨nchen: Hartmann
Gehrke CW, Kuo KC (ed) (1990) Chromatography and Modification of
nucleosides, part A, B and C Analytical Methods for Major and Modified
Nucleosides HPLC, GC, MS, NMR and FT-IR. Amsterdam–Oxford-New
York–Tokyo: Elsevier
Holstege A, Pauw M, Ha ¨ring T, Kirchner R, Pausch J, Gerok W (1986) Die
Wertigkeit einer erho ¨hten Urinausscheidung modifizierter Nukleoside
als Tumormarker beim Kolonkarzinom. Verh Dtsch Ges Inn Med 92:
114–120
Ishiwata S, Itoh K, Yamaguchi KT, Ishida N, Mizugaki M (1995)
Comparison of serum and urinary levels of modified nucleoside, 1-
methyladenosine, in cancer patients using a monoclonal antibody-based
inhibition ELISA. Tohoku J Exp Med 176: 61–68
Koshida K, Harmenberg J, Stendahl U, Wahren B, Borgstrom E, Helstrom
L, Andersson L (1985) Pseudouridine and uridine in normal kidney and
kidney cancer tissues. Urol Res 13: 213–218
Kvist E, Sjolin KE, Iversen J, Nyholm K (1993) Urinary excretion patterns of
pseudouridine and b-aminobutyric acid in patients with tumours of the
urinary bladder. Scand J Urol Nephrol 27: 45–53
Lakings DB, Waalkes TB, Borek E, Gehrke CW, Mrochek JE, Longmore J,
Adamson RH (1977) Composition, associated tissue methyltransferase
activity, and catabolic end products of transfer RNA from carcinogen-
induced hepatoma and normal monkey livers. Cancer Res 37: 285–292
Martinow AJ, Yuen K, Cooper IA, Metthews JP, Juneija S, Wolf M,
Januszewicz H, Prince HM (1998) Prognostic markers of disease activity
in Hodgkin’s disease. Leukaemia Lymphoma 29: 383–389
Masuda M, Nishihira T, Itoh K, Mizugaki M, Ishida N, Mori S (1993) An
immunohistochemical analysis for cancer of the esophagus using
monoclonal antibodies specific for modified nucleosides. Cancer 72:
3571–3578
McEntire JE, Kuo KC, Smith ME, Stalling DL, Richens JW, Zumwalt RW,
Gehrke CW, Papermaster BW (1989) Classification of lung cancer
patients and controls by chromatography of modified nucleosides in
serum. Cancer Res 49: 1057–1062
Nakano K, Nakao T, Schram KH, Hammargren WM, McClure TD, Petersen
E (1993) Urinary excretion of modified nucleosides as biological marker
of RNA turnover in patients with cancer and AIDS. Clin Chim Acta 218:
169–183
Oerlemans F, Lange F (1986) Major and modified nucleosides as markers in
ovarian cancer: a pilot study. Gynecol Obstet Invest 22: 212–217
Rasmuson T, Bjo ¨rk GR (1995) Urinary excretion of pseudouridine and
prognosis of patients with malignant lymphoma. Acta Oncol 34: 61–67
Rasmuson T, Bjo ¨rk GR, Damber L, Jacobsson L, Jeppsson A, Stigbrand T,
Westman G (1987) Tumor markers in mammary carcinoma. Acta Oncol
26: 261–267
Sander G, Topp T, Wieland J, Heller-Scho ¨ch G, Scho ¨ch G (1986) Possible
use of urinary modified RNA metabolites in the measurement of RNA
turnover in the human body. Hum Nutr Clin Nutr 40C: 103–118
Sasco AJ, Rey F, Reynaud C, Bobin JY, Clavel M, Nivelau A (1996) Breast
cancer prognostic significance of some modified urinary nucleosides.
Cancer Lett 108: 157–162
Scho ¨ch G, Sander G, Topp H, Heller-Scho ¨ch G (1990a) Modified nucleo-
sides and nucleobases in urine and serum as selective markers for the
whole-body turnover of tRNA, rRNA and mRNA: future prospects and
impact. In Chromatography and Modification of Nucleosides Part C
Modified Nucleosides in Cancer and Normal Metabolism Methods and
Applications Gehrke CW, Kuo KC (eds) pp C389–C442. Amsterdam:
Elsevier
Scho ¨ch G, Topp H, Held A, Heller-Scho ¨ch G, Baullauf A, Manz F, Sander G
(1990b) Interrelation between whole-body turnover rates of RNA and
protein. Eur J Clin Nutr 44: 389–441
Spiessl B (1993) TNM-Atlas. Heidelberg: Springer
Topp H, Duden R, Scho ¨ch G (1993) 5,6-Dihydrouridine: a marker
ribonucleoside for determining whole body degradation rates of transfer
RNA in man and rats. Clin Chim Acta 218: 73–82
Wagener C (1984) Diagnostic sensitivity diagnostic specificity and
predictive value of the determination of tumour markers. J Clin Chem
Clin Biochem 22: 969–979
Xu G, Schmid HR, Lu X, Liebich HM, Lu P (2000) Excretion pattern
investigation of urinary normal and modified nucleosides of breast
cancer patients by RP–HPLC and factor analysis method. Biomed
Chromatogr 14: 459–463
Yang J, Xu G, Kong H, Zheng Y, Pang T, Yang Q (2002) Artificial neural
network classification on high-performance liquid chromatography
of urinary and serum nucleosides for the clinical diagnosis of cancer.
J Chromatogr B 780: 27–33
Yang J, Xu GW, Theng YF, Kong H, Pang T, Lv S, Yang Q (2004) Diagnosis
of liver cancer using HPLC-based metabonomics avoiding false-positive
result from hepatitis and hepatocirrhosis diseases. J Chromatogr B 813:
59–65
Zhao RG, Xu GB, Yue B, Liebich HM, Zhang Y (1998) Artificial neural
network classification based on capillary electrophoresis of urinary
nucleosides for the clinical diagnosis of tumours. J Chromatogr A 828:
489–496
Zheng YF, Kong HW, Xiong JH, Lv S, Xu GW (2005) Clinical significance
and prognostic value of urinary nucleosides in breast cancer patients.
Clin Biochem 38: 24–30
Modified nucleosides
A Seidel et al
1733
British Journal of Cancer (2006) 94(11), 1726–1733 & 2006 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
s